HOME >> MEDICINE >> NEWS
Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

Clinical Results Will Be Presented Today at 1998 American Society of Hematology (ASH) Conference

San Diego, CA, December 7, 1998 - Maxim Pharmaceuticals (AMEX: MMP, SSE: MAXM) announced updated results from an ongoing Phase II clinical trial of its lead drug Maxamine® in patients with acute myelogenous leukemia (AML). The results from the trial suggest encouraging increases in leukemia-free survival in AML patients treated in remission with Maxamine Therapy.

The updated results will be presented today by Mats Brune, M.D., and Elisabeth Wallhult, R.N., Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden, at the American Society of Hematology Conference in Miami, Florida. "We are very pleased with the number of patients that remain in leukemia-free remission," said Dr. Brune.

The strength of the Phase II data led Maxim to commence a Phase III clinical trial of Maxamine as a remission therapy for AML patients. The Phase III trial, which began earlier this year, is underway in 11 countries and more than 100 clinical sites around the world. "The number of clinical sites that have approached Maxim and agreed to participate in this trial has greatly exceeded our expectations," said Dr. Kurt Gehlsen, chief technical officer of Maxim. "We believe that this interest results from the promising data we have seen in the Phase II trial for this population of patients who have limited options for therapy today."

Background on AML

AML is the most common form of acute leukemia in adults, and prospects for long-term survival are poor for the majority of patients. There are approximately 20,000 new cases and 15,000 deaths caused by AML each year in the United States, Europe and Australia.

Once diagnosed with AML, patients are typically treated with chemotherapy, and the majority achieve complete remission ("CR"). Unfortunately 75-80% of patients who achieve their first CR ("CR1") will relapse, and the medi
'"/>

Contact: Amy Flood
a.flood@noonanrusso.com
415-677-4455 x211
Noonan/Russo Communications
7-Dec-1998


Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2018)... ... November 15, 2018 , ... ... the addition of platelet-rich plasma (PRP) therapies to her leading selection of minimally-invasive ... market, providing intense, all-natural revitalization for any area of the body. Atagi Plastic ...
(Date:11/15/2018)... YORK (PRWEB) , ... November 15, 2018 , ... Made ... is bringing its traveling exhibit — Seen — to New York this month. The ... offices. , “I wanted to create environment that showcases mental health issues in a ...
(Date:11/15/2018)... ... ... Relief Scout is excited to announce its official launch. Relief Scout is an ... growing market. , First, Relief Scout adds clarity to the market by providing ... understand what CBD product is best for their specific ailment, level of discomfort, medicine ...
(Date:11/15/2018)... ... November 15, 2018 , ... Mothers and babies across ... unique collaboration that puts vital health education resources right at their fingertips. The ... Promise Health Plan effective 1/1/19), an affiliate of Blue Shield of California, and ...
(Date:11/15/2018)... ... ... West Virginia and Mississippi may have the two highest obesity rates in the ... number of weight-loss surgeries per capita, and have two of the worst state economies, ... in the 50 states plus the nation’s capital. The findings* were presented today at ...
Breaking Medicine News(10 mins):
(Date:11/16/2018)... ... November 16, 2018 , ... ... products, is thrilled to announce the launch of its newly redesigned website. ... of the company's mission and products. The newly redesigned website will be regularly ...
(Date:11/16/2018)... ... November 16, 2018 , ... SPH Analytics (SPH), a leader in ... SPH #1 in the Health Insurer/Managed Care Plan category and #3 Overall on its ... total number of clients and is based on reported data for 2017 performance. ...
(Date:11/16/2018)... ... 16, 2018 , ... Trident University International (Trident) has enhanced ... a desire to maintain a high level of academic standards and to best ... and returning students starting in the January 2019 Fastrac session. , This ...
Breaking Medicine Technology:
Cached News: